Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
Turnstone Biologics Corp. is set to present at the 2024 Bank of America Securities Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Turnstone Biologics Corp. is set to present at the 2024 Bank of America Securities Health Care Conference. The company, listed on Nasdaq as TSBX, focuses on developing innovative treatments for solid tumors through Selected TIL therapy. The presentation by the President and CEO, Sammy Farah, will take place on May 15, 2024, in Las Vegas. Investors can access the live webcast on the company's website and arrange one-on-one meetings with senior management.
Details
News Market Reaction – TSBX
The recorded move for TSBX in the trading session of this news was +1.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. The presentation will begin at 11:35 a.m. P.T. / 2:35 p.m. E.T.
To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company’s website at www.turnstonebio.com. A webcast replay will be available for a limited period.
Members of Turnstone’s senior management will also be available for one-on-one meetings during the conference. Interested investors should contact their Bank of America Securities representative for further information.
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.